Astellas Pharma Inc. reached an agreement Thursday with XenoPort Inc., a U.S. pharmaceutical company, giving it exclusive rights to sell in Japan and five other Asian markets a painkiller being developed by the U.S. firm, the two companies said.
Under the licensing agreement, Astellas will pay $85 million to the California-based company to market XenoPort's leading product candidate, Astellas said. It will also pay royalties based on sales volume.
The prospective drug is an improved version of gabapentin, a medication used in the treatment of epileptic seizures and nerve pain.
Astellas plans to begin the first phase of clinical tests on the drug in mid-2006.
The five other Asian markets to which Astellas has acquired exclusive rights to market the product are Indonesia, the Philippines, South Korea, Thailand and Taiwan.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.